Testing Experimental Treatment
common.study.values.description
“Phase 1, for Multiple Doses of HM15136 in Obese or Overweight Subjects With Comorbidities”
The planned period of each cohort is 22 weeks including subject screening, treatments for 12 weeks, and follow up period.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Drug - HM15136
In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 36 subjects, divided in 2 cohorts with 18 subjects (HM15136 group 9 subjects, placebo group 9 subjects) per cohort. However, Part 2 study may not be conducted after the review of the safety data in Part 1.
Drug - Placebo
In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 36 subjects, divided in 2 cohorts with 18 subjects (HM15136 group 9 subjects, placebo group 9 subjects) per cohort. However, Part 2 study may not be conducted after the review of the safety data in Part 1.
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 1, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of HM15136 in Obese or Overweight Subjects With Comorbidities
common.study.values.clinical-trial-id
NCT04167553
participant.views.study.view.id
bo2xKa
